RAD51 and colorectal cancer: Using this strategy, we found that topoisomerase and cyclin-dependent kinase (CDK) inhibitors potentially reverse ReCa signatures and inhibit the growth of colorectal cancer (CRC) cell lines closely representing ReCa signatures.